TY  - JOUR
T1  - RETROSPECTIVE  ANALYSIS  OF  CHRONIC  MYELOID  LEUKEMIA  PATIENTS  IN  TRAKYA UNIVERSITY SCHOOL OF MEDICINE
AU  - Akay, Fatih Erkan
AU  - Koçyiğit, Beliz
AU  - Tan, Berfin
AU  - Atlı, Emine İkbal
AU  - Baş, Volkan
AU  - Kırkızlar, Hakkı Onur
PY  - 2019
DA  - October
JF  - Turkish Medical Student Journal
JO  - TMSJ
PB  - Trakya Üniversitesi
WT  - DergiPark
SN  - 2148-4724
SP  - 70
EP  - 74
VL  - 6
IS  - 3
LA  - en
AB  - Aims: This study aims to establish the data; including demographic features, molecular response status, disease characteristics, and  survival  rate  of  chronic  myeloid  leukemia  patients  treated  with  tyrosine  kinase  inhibitors  in  Trakya  University  School  of  Medicine.    Methods: In this study, the data of 102 patients over 18 years old who were diagnosed with chronic myeloid leukemia in Trakya University School of Medicine between January 2003-October 2019 were analyzed retrospectively. Data was analyzed using SPSS 23.0.0.0.  Results: The total number of patients in the study was 102. There were 95 (93.1%) patients on chronic phase and 6 (5.9%) patients on accelerated phase. Eighty-three (81.4%) of the patients had at least a major molecular response and 17 (16.7%) patients could not achieve at least a major molecular response. Conclusion: As our study showed, first line treatment with imatinib may not be enough for some of the patients to recover and therefore different TKIs such as dasatinib, nilotinib, bo-sutinib, and ponatinib are being used in the treatment of CML. Inadequate response, drug side effects and incompliances are the causes of switching the drug choice. Further studies are needed to thoroughly reveal the epidemiology and treatment regimens.Keywords: Chronic myeloid leukemia, tyrosine kinase, neoplasms
KW  - Chronic myeloid leukemia
KW  - tyrosine kinase
KW  - neoplasms
CR  - 1. Faderl S, Talpaz M, Estrov Z et al. The biology of chronic myeloid leukemia. New England Journal of Medicine 1999;341(3):164–72.
CR  - 2.  Kurzrock  G,  Gutterman  J,  Talpaz  M.  The  molecular  genetics  of  Philadelphia  chromosome-positive  leukemias.  N  Engl  J  Med  1988;319:990-8.
CR  - 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.
CR  - 4. Braziel RM, Shipp MA, Feldman AL et al. Molecular diagnostics. Hematology 2003;(1):279-93.
CR  - 5. Baccarani M, Deininger MW, Rosti G et al. European Leukemia-Net recommendations for the management of chronic myeloid leu-kemia: 2013. Blood 2013;122(6):872–84.
CR  - 6. Radich JP, Deininger M, Abboud CN et al. Chronic myeloid leu-kemia,  version  1.2019,  NCCN  clinical  practice  guidelines  in  on-cology.  Journal  of  the  National  Comprehensive  Cancer  Network  2019;16:1108–35.
CR  - 7. Hanfstein B, Müller MC, Hehlmann R et al. Early molecular and cytogenetic  response  is  predictive  for  long-term  rogression-free  and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096–102.
CR  - 8. Hochhaus A, Saussele S, Rosti G et al. Chronic myeloid leukaemia: ESMO  clinical  practice  guidelines  for  diagnosis,  treatment  and  fol-low-up. Annals of Oncology 2017;28(4):41-51.
CR  - 9. Sahin F, Saydam G, Comert M et al. Turkish chronic myeloid leu-kemia study: retrospective sectional analysis of CML patients. Turk J Hematol 2013;30:351-8.
CR  - 10.  O’Brien  SG,  Guilhot  F,  Larson  RA  et  al.  Imatinib  compared  with interferon and low-dose cytarabine for newly diagnosed chro-nic-phase  chronic  myeloid  leukemia.  N  Engl  J  Med  2003;348:994-1004.
CR  - 11.  Druker  BJ,  Guilhot  F,  O’Brien  SG  et  al.  Five-year  follow-up  of  patients  receiving  imatinib  for  chronic  myeloid  leukemia.  N  Engl  J  Med 2006;355:2408-17.
CR  - 12. Roy L, Guilhot J, Krahnke T et al. Survival advantage from imati-nib compared with combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-84.ü
CR  - 13. Bittencourt H, Funke V, Fogliatto L et al. Imatinib mesylate versus allogeneic  BMT  for  patients  with  chronic  myeloid  leukemia  in  first  chronic phase. Bone Marrow Transplant 2008;42:597-600.
CR  - 14.  National  Cancer  Institute.  Surveillance,  Epidemiology,  and  End  Results Program. (online) (cited 2019 August 5). Available from: UR-L:https://seer.cancer.gov.
CR  - 15. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 2018;93(3):442-59.
CR  - 16. Shanmuganathan N, Hiwase DK, Ross DM. Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leukemia & Lymphoma 2017;58(12):2799–810.
CR  - 17.  Russo  RA,  Breccia  M,  Abruzzese  E  et  al.  Outcome  of  82  chro-nic  myeloid  leukemia  patients  treated  with  nilotinib  or  dasatinib  after  failure  of  two  prior  tyrosine  kinase  inhibitors.  Haematologica  2013;98:399–403.
CR  - 18. Khoury HJ, Cortes JE, Kantarjian HM et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403–12.
UR  - https://dergipark.org.tr/tr/pub/tmsj/issue//640239
L1  - https://dergipark.org.tr/tr/download/article-file/843906
ER  -